Sleep Apnea, ObstructiveSNORTNCT06330116
Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea
A study testing IQoro, eXciteosa and Grouptraining in people with Sleep Apnea, Obstructive and Snoring, run by Region Västerbotten at 3 sites in 2 countries.
Trial summary
Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Sleep Apnea, Obstructive, Snoring
- What is being tested?
- IQoro, eXciteosa and Grouptraining
- Type of treatment
- Pill or oral medicine, Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 141 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 1 May 2024to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women with AHI 10 - 29 seeking for problems with snoring and obstructive sleep apnea, age 18 to 75.
Who cannot join
- Subjects with previous surgery of the soft palate, 9 < AHI > 29, smokers, New York Heart Association Functional Classification, NYHA ≥ 3. BMI >34,9.
Trial locations and contacts
3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
3 sites in 2 countries
Sweden2 sites
Skåne University Hospital
Lund, Skåne County, 22100
Region Västerbotten
Umeå, Västerbotten County, 901 85
About this study
Official title: A Comparison of Three Different Forms of Oral Myofunctional Training (OMT) as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea
Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these different training methods can reduce snoring and affect the level of sleepiness and quality of life. Study design The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase, and follow-up measurements.
Methods 141 consecutive adult subjects, 71 men and 70 women referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sites, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the three different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Participants in Umeå will be randomized to either training with IQoro® or serving as controls. Participants in Köge will be randomized to either training with Exciteosa®, group training, or controls.
Read more
The primary outcome is a change in AHI before and after three months of training with the different methods according to overnight ambulatory sleep apnea recordings.
The secondary outcomes are change in snoring frequency, sound level dB (A) according to a questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ), daytime sleepiness using the Epworth Sleepiness Scale (ESS), change in quality of life using the short form -36 (SF-36) and muscle strength in tongue before and after treatment.
Read the detailed description
Introduction/Background
Snoring and obstructive sleep apnea (OSA) are common among the adult population; a mean of 22% and 17% of the women are affected. Obstructive sleep apnea is related to several negative health effects, such as sleepiness, hypertension, cardiovascular disease, and cognitive impairment. Continuous positive airway pressure (CPAP), oral appliances (OA), as well as oropharyngeal surgery in selected cases are available as a treatment for OSA. The same methods can be used for reducing snoring, but the cost for the devices is high, and the compliance tends to be low, although snoring affects the individual as well as the bed partner. Snoring produces vibrations in the upper airway, and over time, it can affect both the motor and sensory function of the tissue in the upper airway. The deterioration process is unknown, but previously published data shows a correlation between the level of snoring/OSA and altered sensory and motor function. This is probably due to the adverse effects of the vibrations and stretching of the nerves and muscles in the airway during snoring and apneas. Our and other research groups have presented similar results and hypothesize that the deterioration may explain why the airway slowly tends to collapse more frequently. This may also explain why more than half of the habitual snorers show deviant swallowing function and thereby have a higher risk of aspiration. It is unknown if this degenerative process of the upper airway is possible to slow down, stop or perhaps even be reversed and thereby improve the sensory and motor function by treatment that decrease or determine snoring and OSA. However, recent data give promising indications that myofunctional training of the upper airway can decrease levels and intensity of snoring and reduce the apnea-hypopnea index (AHI).
Oral screen training can affect brain plasticity and have a strengthening effect on oral and pharyngeal muscles. Oral screen training is used to improve oral and pharyngeal muscle function and has been reported to improve swallowing function in patients suffering from dysphagia including aspiration after stroke. Further, it has been reported to be efficient for the treatment of dysphagia caused by other conditions.
Daily neuromuscular electrical training (NMES) by an oral device eXciteosa® has shown promising results in patients with primary snoring and mild sleep apnea, reducing objective and subjective snoring. Orofacial training guided by an occupational therapist (group training) has also shown positive results in adhering to the training program and affecting the AHI, reducing it in persons aged 60 and younger.
The aim of the present study is, therefore, to assess 1) the impact of three different training methods to reduce AHI among adults with mild to moderate sleep apnea and 2) if the oral screen training can lower the level and intensity of snoring, change levels of sleepiness, quality of life and strength of the tongue muscle.
Material and methods
Subjects and procedure In total 141 consecutive adult subjects, 71 men and 70 women, referred to Umeå University Hospital and Köge University Hospital, due to symptoms of snoring and/or mild to moderate sleep apnea, will be included. The subjects included in Umea will get three months of intervention with oral screen training or serve as controls. The subjects included in Köge will get either a three-month intervention with orofacial group training led by an occupational therapist, three months intervention with a daytime mouth device for muscular training, eXciteosa® or serve as controls. At baseline, all subjects will undergo two overnight ambulatory sleep apnea recordings and answer questionnaires regarding snoring, daytime sleepiness, and quality of life. The demography, including sex, age, and BMI, will be recorded. Tounge strength will be measured.
In Umeå, the participants will be randomly assigned to either an initial three-month intervention with oral screen training or a three-month intervention delay, serving as controls. In Köge, the participants will be randomly assigned to either a three-month intervention with eXciteosa®, group training with an occupational therapist, or serve as controls. After three months, all the above questions and parameters will be registered again.
Inclusion criteria are men and women with AHI 10 - 29 seeking for problems with snoring and obstructive sleep apnea, age 18 to 75.
Exclusion criteria are subjects with previous soft palate surgery, 9 < AHI > 29, smokers, New York Heart Association Functional Classification, NYHA ≥ 3. BMI >34,9.
Main outcome measurements The primary outcome is the change in the apnea-hypopnea index (AHI) before and after three months of training with one of the modalities.
Secondary outcome measurements The secondary outcomes are a change in snoring frequency and sound level dB (A) and a a questionnaire concerning snoring, the Basic Nordic Sleep Questionnaire (BNSQ).
Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS) change in quality of life using the short form -36 (SF-36) and change in muscle strength before and after treatment.
Oral screen (Only in Sweden) Strength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro®). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. The OS is placed pre-dentally behind closed lips. The participant pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day.
Neuromuscular electrical training (NMES) (Only in Denmark) Strength training of the oral and pharyngeal muscles is performed by an oral device used for twenty minutes every day (eXciteosa®). The device gives electrical pulses to the surrounding tissue, mainly the tongue.
Group training with an occupational therapist (Only in Denmark) Strength training of the oral and pharyngeal muscles is performed in a group led by an occupational therapist.
Sleep apnea recordings The investigators will use two types of recording devices, Nox-T3® (Nox-T3®, Nox Medical Inc.
Reykjavik, Iceland) and SleepImage® System (MyCardio LLC, Denver, CO, USA) In the overnight home sleep studies, recordings will be scored manually (Nox-T3®), and the scorer is blinded to the treatment (blinded endpoint). All recordings will be done over two nights, at baseline and follow-up to minimize the effect of night-to-night variability.
The duration of sleep will be estimated from the recordings. An apnea is defined as a drop in the peak thermal sensor excursion of > 90 of the baseline lasting at least 10 seconds, while a hypopnea is defined as a 50% reduction in airflow compared with baseline, combined with an oxygen desaturation of > 3%.
Obstructive sleep apnea is defined as a mean of five or more obstructive apneas and hypopneas per hour of sleep. Mild sleep apnea is considered when the apnea-hypopnea index is 5 to < 15, moderate sleep apnea when the apnea-hypopnea index is 15 to < 30, and severe sleep apnea when the apnea-hypopnea index is > 30.
The snoring frequency and sound level dB (A) will be measured with a microphone within the recording device (Nox-T3®) and a questionnaire regarding the level and frequencies of the snoring (BNSQ).
Additionally, the investigators will also use a new device called Sleepimage®. The device measures plethysmography trace, heart (pulse) rate, heart (pulse) rate variability, respiration, blood oxygenation (SpO2), and actigraphy. The device is a ring worn on any finger on the left hand and collects sleep data during the night. The result is then translated into a report giving data about sleep quality, any sleep pathology, and sleep duration. The device has FDA approval At present, there is no "golden standard" for measuring snoring. However, the methods and devices have improved, and a recent comparison of different tools for measuring snoring suggested the use of the T3 advice for the recordings.
Measuring strength:
Tounge strength is measured with the Iowa Oral Performance Instrument, IOPI®.
Questionnaires:
The Basic Nordic Sleep Questionnaire (BNSQ) BNSQ was developed in Nordic countries to develop a standardized questionnaire. The task force developing it was set up in 1988 by the Scandinavian Sleep Research Society. It consists of 21 questions on sleep, evaluating the past three months. The questions can be answered on a five-point scale, 1 to 5. It has been translated into Swedish and Danish.
Epworth Sleepiness Scale (ESS) ESS is a validated questionnaire assessing the probability of falling asleep in eight different situations in daily life with four alternative answers ranging from 0-3. The score ranges from 0-24, and the higher the score, the higher the level of daytime sleepiness. The ESS has been proven to correlate to the AHI in the Sleep Heart Health Study, showing higher levels of the ESS when the AHI was higher. There is also a correlation between the incidences of road traffic accidents and the ESS, as well as health-related questions relating to quality of life and the ESS. Daytime sleepiness is considered at a summary score of above 10. It has been translated into Swedish and Danish.
Short form 36 (SF-36) The SF-36 is a validated questionnaire that evaluates the quality of life in eight different health-related domains. It has been translated into Swedish and Danish.
Statistics A power calculation was performed based on Guimaraes et al.2009 results. The AHI was used in the calculation. Independent samples t-test, two-sided, anticipated effect size (Cohen's d) 0.8 (high), power ≥80%, probability level 5%. This gives a minimal sample size of 26 per group. The expected dropout of patients during the trial is 25% corresponding to a total of 9 patients in each group. To accommodate for this potential, the sample size was increased to 105 (35 in each group).
The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase and follow-up measurements, and controls without intervention. Primary and secondary outcomes are values of AHI, snoring, BNSQ, ESS, and SF-36. These measures will be compared for baseline data and follow-up data by applying an independent-samples t-test, chi2 for proportion. ANCOVA will be used to estimate adjusted differences between the groups, adjusting for baseline values. Statistical analyses will be conducted using SPSS® version 28. A statistically significant level is defined as P<0,05.
Ethics The study has Ethical approval in Sweden and Denmark. The participants, men, and women, included in the study will be informed both orally and in written information before leaving informed consent. The participants can, without explanation, end the study without any negative impact on future care.
- Conditions
- Sleep Apnea, Obstructive, Snoring
- Being tested
- IQoro, eXciteosa, Grouptraining
- Medical subject headings
- Sleep Apnea, Obstructive, Snoring
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IQoroDevice
Please refer to arm/group description for information
eXciteosaDevice
Please refer to arm/group description for information
GrouptrainingBehavioural
Please refer to arm/group description for information
| Study group | Role | What they receive |
|---|---|---|
| Oral screen | Active comparator | Strength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. (9) The OS is placed pre-dentally behind closed lips. The patient pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day. Training for 3 months. Receives: Device: IQoro |
| Neuromuscular electrical training (NMES) | Active comparator | Strength training of the oral and pharyngeal muscles is performed by an oral device used for 20 minutes every day (eXciteosa). The device gives electrical pulses to the surrounding tissue, mainly the tongue. Training for 3 months. Receives: Device: eXciteosa |
| Group training with an occupational therapist | Active comparator | Strength training of the oral and pharyngeal muscles is performed in group, led by an occupational therapist. Training for 3 months. Receives: Behavioral: Grouptraining |
What is being measured
The primary outcome is the main question the study is designed to answer.
Apnea-hypopnea index (AHI)
The primary outcome is the change in the apnea-hypopnea index (AHI) before and after three months of intervention or control.
months of training with one of the modalities, according to two overnight ambulatory sleep apnea recordings.
Measured: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Secondary outcomes (3)
Questionnaires
Change in results from questionnaires concerning snoring, the Basic Nordic Sleep Questionnaire (BNSQ). Daytime sleepiness assessed using the Epworth Sleepiness Scale (ESS) change in quality of life using the short form -36 (SF-36) after 3 months of training or control.
Measured: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Snoring
Change in snoring frequency and sound level dB (A) after 3 months of training or controls.
Measured: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Tounge strength
Change in muscle strength before and after treatment for 3 months of training or serving as controls. For measuring a device called IOPI, Iowa Oral Performance Instrument, is used.
Measured: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2024
- Study start1 May 2024
- Primary completion31 Dec 2025 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for Sleep Apnea, ObstructiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 141 consecutive adult subjects, 71 men and 70 women, referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sights, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the 3 different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Patients in Umeå will be randomized to either training with IQoro or serving as controls. Patients in Köge will be randomized to either training with Exciteosa group training, or controls.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 141 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Region Västerbotten
- Sponsor type
- Other government
- Collaborators
- Interreg, Umeå University
- Responsible party
- Sponsor
- Investigators
- Thorbjörn Holmlund, PhD, Principal investigator, Region Västerbotten
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06330116
- Sponsor's protocol ID
- 2023-05348-01
- Other IDs
- 2023
- Acronym
- SNORT
- Status last verified
- Nov 2024
- First submitted
- 12 Mar 2024
- Last updated
- 29 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: Data will be shared with other researchers upon request. The data will be anonymized before sharing to avoid being traced back to a single study participant.
Publications
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. doi: 10.1056/NEJM199304293281704.
PubMed 8464434Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. J Thorac Dis. 2015 Aug;7(8):1311-22. doi: 10.3978/j.issn.2072-1439.2015.06.11.
PubMed 26380759Wozniak DR, Lasserson TJ, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2014 Jan 8;(1):CD007736. doi: 10.1002/14651858.CD007736.pub2.
PubMed 24399660Lim J, Lasserson TJ, Fleetham J, Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004435. doi: 10.1002/14651858.CD004435.pub3.
PubMed 16437488Svanborg E. Upper airway nerve lesions in obstructive sleep apnea. Am J Respir Crit Care Med. 2001 Jul 15;164(2):187-9. doi: 10.1164/ajrccm.164.2.2105010c. No abstract available.
PubMed 11463584Sunnergren O, Brostrom A, Svanborg E. Soft palate sensory neuropathy in the pathogenesis of obstructive sleep apnea. Laryngoscope. 2011 Feb;121(2):451-6. doi: 10.1002/lary.21371.
PubMed 21271605Jaghagen EL, Berggren D, Isberg A. Swallowing dysfunction related to snoring: a videoradiographic study. Acta Otolaryngol. 2000 Mar;120(3):438-43. doi: 10.1080/000164800750000702.
PubMed 10894423Levring Jaghagen E, Franklin KA, Isberg A. Snoring, sleep apnoea and swallowing dysfunction: a videoradiographic study. Dentomaxillofac Radiol. 2003 Sep;32(5):311-6. doi: 10.1259/dmfr/29209140.
PubMed 14709606Jaghagen EL, Berggren D, Dahlqvist A, Isberg A. Prediction and risk of dysphagia after uvulopalatopharyngoplasty and uvulopalatoplasty. Acta Otolaryngol. 2004 Dec;124(10):1197-203. doi: 10.1080/00016480410017954.
PubMed 15768818Jaghagen EL, Bodin I, Isberg A. Pharyngeal swallowing dysfunction following treatment for oral and pharyngeal cancer--association with diminished intraoral sensation and discrimination ability. Head Neck. 2008 Oct;30(10):1344-51. doi: 10.1002/hed.20881.
PubMed 18720519Camacho M, Certal V, Abdullatif J, Zaghi S, Ruoff CM, Capasso R, Kushida CA. Myofunctional Therapy to Treat Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Sleep. 2015 May 1;38(5):669-75. doi: 10.5665/sleep.4652.
PubMed 25348130Hagg M, Tibbling L. Effect of IQoro(R) training on impaired postural control and oropharyngeal motor function in patients with dysphagia after stroke. Acta Otolaryngol. 2016 Jul;136(7):742-8. doi: 10.3109/00016489.2016.1145797. Epub 2016 Feb 29.
PubMed 26924256Partinen M, Gislason T. Basic Nordic Sleep Questionnaire (BNSQ): a quantitated measure of subjective sleep complaints. J Sleep Res. 1995 Jun;4(S1):150-155. doi: 10.1111/j.1365-2869.1995.tb00205.x.
PubMed 10607192Arnardottir ES, Isleifsson B, Agustsson JS, Sigurdsson GA, Sigurgunnarsdottir MO, Sigurdarson GT, Saevarsson G, Sveinbjarnarson AT, Hoskuldsson S, Gislason T. How to measure snoring? A comparison of the microphone, cannula and piezoelectric sensor. J Sleep Res. 2016 Apr;25(2):158-68. doi: 10.1111/jsr.12356. Epub 2015 Nov 9.
PubMed 26553758Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992 Aug;15(4):376-81. doi: 10.1093/sleep/15.4.376.
PubMed 1519015
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparison of Three Different Forms of Oral Myofunctional Training (OMT) as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea
- ClinicalTrials.gov ID
- NCT06330116
- Acronym / sponsor ID
- SNORT / 2023-05348-01
- Conditions
- Sleep Apnea, Obstructive, Snoring
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 141 participants (estimated)
- Lead sponsor
- Region VästerbottenOther government
- Collaborators
- Interreg, Umeå University
- Study start
- 1 May 2024 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 26 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these different training methods can reduce snoring and affect the level of sleepiness and quality of life. Study design The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase, and follow-up measurements.
Methods 141 consecutive adult subjects, 71 men and 70 women referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sites, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the three different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Participants in Umeå will be randomized to either training with IQoro® or serving as controls. Participants in Köge will be randomized to either training with Exciteosa®, group training, or controls.
The primary outcome is a change in AHI before and after three months of training with the different methods according to overnight ambulatory sleep apnea recordings.
The secondary outcomes are change in snoring frequency, sound level dB (A) according to a questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ), daytime sleepiness using the Epworth Sleepiness Scale (ESS), change in quality of life using the short form -36 (SF-36) and muscle strength in tongue before and after treatment.
Detailed description
Introduction/Background
Snoring and obstructive sleep apnea (OSA) are common among the adult population; a mean of 22% and 17% of the women are affected. Obstructive sleep apnea is related to several negative health effects, such as sleepiness, hypertension, cardiovascular disease, and cognitive impairment. Continuous positive airway pressure (CPAP), oral appliances (OA), as well as oropharyngeal surgery in selected cases are available as a treatment for OSA. The same methods can be used for reducing snoring, but the cost for the devices is high, and the compliance tends to be low, although snoring affects the individual as well as the bed partner. Snoring produces vibrations in the upper airway, and over time, it can affect both the motor and sensory function of the tissue in the upper airway. The deterioration process is unknown, but previously published data shows a correlation between the level of snoring/OSA and altered sensory and motor function. This is probably due to the adverse effects of the vibrations and stretching of the nerves and muscles in the airway during snoring and apneas. Our and other research groups have presented similar results and hypothesize that the deterioration may explain why the airway slowly tends to collapse more frequently. This may also explain why more than half of the habitual snorers show deviant swallowing function and thereby have a higher risk of aspiration. It is unknown if this degenerative process of the upper airway is possible to slow down, stop or perhaps even be reversed and thereby improve the sensory and motor function by treatment that decrease or determine snoring and OSA. However, recent data give promising indications that myofunctional training of the upper airway can decrease levels and intensity of snoring and reduce the apnea-hypopnea index (AHI).
Oral screen training can affect brain plasticity and have a strengthening effect on oral and pharyngeal muscles. Oral screen training is used to improve oral and pharyngeal muscle function and has been reported to improve swallowing function in patients suffering from dysphagia including aspiration after stroke. Further, it has been reported to be efficient for the treatment of dysphagia caused by other conditions.
Daily neuromuscular electrical training (NMES) by an oral device eXciteosa® has shown promising results in patients with primary snoring and mild sleep apnea, reducing objective and subjective snoring. Orofacial training guided by an occupational therapist (group training) has also shown positive results in adhering to the training program and affecting the AHI, reducing it in persons aged 60 and younger.
The aim of the present study is, therefore, to assess 1) the impact of three different training methods to reduce AHI among adults with mild to moderate sleep apnea and 2) if the oral screen training can lower the level and intensity of snoring, change levels of sleepiness, quality of life and strength of the tongue muscle.
Material and methods
Subjects and procedure In total 141 consecutive adult subjects, 71 men and 70 women, referred to Umeå University Hospital and Köge University Hospital, due to symptoms of snoring and/or mild to moderate sleep apnea, will be included. The subjects included in Umea will get three months of intervention with oral screen training or serve as controls. The subjects included in Köge will get either a three-month intervention with orofacial group training led by an occupational therapist, three months intervention with a daytime mouth device for muscular training, eXciteosa® or serve as controls. At baseline, all subjects will undergo two overnight ambulatory sleep apnea recordings and answer questionnaires regarding snoring, daytime sleepiness, and quality of life. The demography, including sex, age, and BMI, will be recorded. Tounge strength will be measured.
In Umeå, the participants will be randomly assigned to either an initial three-month intervention with oral screen training or a three-month intervention delay, serving as controls. In Köge, the participants will be randomly assigned to either a three-month intervention with eXciteosa®, group training with an occupational therapist, or serve as controls. After three months, all the above questions and parameters will be registered again.
Inclusion criteria are men and women with AHI 10 - 29 seeking for problems with snoring and obstructive sleep apnea, age 18 to 75.
Exclusion criteria are subjects with previous soft palate surgery, 9 < AHI > 29, smokers, New York Heart Association Functional Classification, NYHA ≥ 3. BMI >34,9.
Main outcome measurements The primary outcome is the change in the apnea-hypopnea index (AHI) before and after three months of training with one of the modalities.
Secondary outcome measurements The secondary outcomes are a change in snoring frequency and sound level dB (A) and a a questionnaire concerning snoring, the Basic Nordic Sleep Questionnaire (BNSQ).
Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS) change in quality of life using the short form -36 (SF-36) and change in muscle strength before and after treatment.
Oral screen (Only in Sweden) Strength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro®). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. The OS is placed pre-dentally behind closed lips. The participant pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day.
Neuromuscular electrical training (NMES) (Only in Denmark) Strength training of the oral and pharyngeal muscles is performed by an oral device used for twenty minutes every day (eXciteosa®). The device gives electrical pulses to the surrounding tissue, mainly the tongue.
Group training with an occupational therapist (Only in Denmark) Strength training of the oral and pharyngeal muscles is performed in a group led by an occupational therapist.
Sleep apnea recordings The investigators will use two types of recording devices, Nox-T3® (Nox-T3®, Nox Medical Inc.
Reykjavik, Iceland) and SleepImage® System (MyCardio LLC, Denver, CO, USA) In the overnight home sleep studies, recordings will be scored manually (Nox-T3®), and the scorer is blinded to the treatment (blinded endpoint). All recordings will be done over two nights, at baseline and follow-up to minimize the effect of night-to-night variability.
The duration of sleep will be estimated from the recordings. An apnea is defined as a drop in the peak thermal sensor excursion of > 90 of the baseline lasting at least 10 seconds, while a hypopnea is defined as a 50% reduction in airflow compared with baseline, combined with an oxygen desaturation of > 3%.
Obstructive sleep apnea is defined as a mean of five or more obstructive apneas and hypopneas per hour of sleep. Mild sleep apnea is considered when the apnea-hypopnea index is 5 to < 15, moderate sleep apnea when the apnea-hypopnea index is 15 to < 30, and severe sleep apnea when the apnea-hypopnea index is > 30.
The snoring frequency and sound level dB (A) will be measured with a microphone within the recording device (Nox-T3®) and a questionnaire regarding the level and frequencies of the snoring (BNSQ).
Additionally, the investigators will also use a new device called Sleepimage®. The device measures plethysmography trace, heart (pulse) rate, heart (pulse) rate variability, respiration, blood oxygenation (SpO2), and actigraphy. The device is a ring worn on any finger on the left hand and collects sleep data during the night. The result is then translated into a report giving data about sleep quality, any sleep pathology, and sleep duration. The device has FDA approval At present, there is no "golden standard" for measuring snoring. However, the methods and devices have improved, and a recent comparison of different tools for measuring snoring suggested the use of the T3 advice for the recordings.
Measuring strength:
Tounge strength is measured with the Iowa Oral Performance Instrument, IOPI®.
Questionnaires:
The Basic Nordic Sleep Questionnaire (BNSQ) BNSQ was developed in Nordic countries to develop a standardized questionnaire. The task force developing it was set up in 1988 by the Scandinavian Sleep Research Society. It consists of 21 questions on sleep, evaluating the past three months. The questions can be answered on a five-point scale, 1 to 5. It has been translated into Swedish and Danish.
Epworth Sleepiness Scale (ESS) ESS is a validated questionnaire assessing the probability of falling asleep in eight different situations in daily life with four alternative answers ranging from 0-3. The score ranges from 0-24, and the higher the score, the higher the level of daytime sleepiness. The ESS has been proven to correlate to the AHI in the Sleep Heart Health Study, showing higher levels of the ESS when the AHI was higher. There is also a correlation between the incidences of road traffic accidents and the ESS, as well as health-related questions relating to quality of life and the ESS. Daytime sleepiness is considered at a summary score of above 10. It has been translated into Swedish and Danish.
Short form 36 (SF-36) The SF-36 is a validated questionnaire that evaluates the quality of life in eight different health-related domains. It has been translated into Swedish and Danish.
Statistics A power calculation was performed based on Guimaraes et al.2009 results. The AHI was used in the calculation. Independent samples t-test, two-sided, anticipated effect size (Cohen's d) 0.8 (high), power ≥80%, probability level 5%. This gives a minimal sample size of 26 per group. The expected dropout of patients during the trial is 25% corresponding to a total of 9 patients in each group. To accommodate for this potential, the sample size was increased to 105 (35 in each group).
The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase and follow-up measurements, and controls without intervention. Primary and secondary outcomes are values of AHI, snoring, BNSQ, ESS, and SF-36. These measures will be compared for baseline data and follow-up data by applying an independent-samples t-test, chi2 for proportion. ANCOVA will be used to estimate adjusted differences between the groups, adjusting for baseline values. Statistical analyses will be conducted using SPSS® version 28. A statistically significant level is defined as P<0,05.
Ethics The study has Ethical approval in Sweden and Denmark. The participants, men, and women, included in the study will be informed both orally and in written information before leaving informed consent. The participants can, without explanation, end the study without any negative impact on future care.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- 141 consecutive adult subjects, 71 men and 70 women, referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sights, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the 3 different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Patients in Umeå will be randomized to either training with IQoro or serving as controls. Patients in Köge will be randomized to either training with Exciteosa group training, or controls.
| Arm | Type | Receives |
|---|---|---|
| Oral screen | Active comparator | Device: IQoroStrength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. (9) The OS is placed pre-dentally behind closed lips. The patient pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day. Training for 3 months. |
| Neuromuscular electrical training (NMES) | Active comparator | Device: eXciteosaStrength training of the oral and pharyngeal muscles is performed by an oral device used for 20 minutes every day (eXciteosa). The device gives electrical pulses to the surrounding tissue, mainly the tongue. Training for 3 months. |
| Group training with an occupational therapist | Active comparator | Behavioral: GrouptrainingStrength training of the oral and pharyngeal muscles is performed in group, led by an occupational therapist. Training for 3 months. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Men and women with AHI 10 - 29 seeking for problems with snoring and obstructive sleep apnea, age 18 to 75.
Key exclusion criteria (1 listed)
- Subjects with previous surgery of the soft palate, 9 < AHI > 29, smokers, New York Heart Association Functional Classification, NYHA ≥ 3. BMI >34,9.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IQoroPlease refer to arm/group description for information | Device | Oral screen |
| eXciteosaPlease refer to arm/group description for information | Device | Neuromuscular electrical training (NMES) |
| GrouptrainingPlease refer to arm/group description for information | Behavioural | Group training with an occupational therapist |
Primary outcome
Apnea-hypopnea index (AHI)
Time frame: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
The primary outcome is the change in the apnea-hypopnea index (AHI) before and after three months of intervention or control. months of training with one of the modalities, according to two overnight ambulatory sleep apnea recordings.
3 secondary outcomes
Questionnaires
Time frame: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Snoring
Time frame: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Tounge strength
Time frame: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2025.
- Results publication: PubMed 8464434Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. doi: 10.1056/NEJM199304293281704.
- Results publication: PubMed 26380759Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. J Thorac Dis. 2015 Aug;7(8):1311-22. doi: 10.3978/j.issn.2072-1439.2015.06.11.
- Results publication: PubMed 24399660Wozniak DR, Lasserson TJ, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2014 Jan 8;(1):CD007736. doi: 10.1002/14651858.CD007736.pub2.
- Results publication: PubMed 16437488Lim J, Lasserson TJ, Fleetham J, Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004435. doi: 10.1002/14651858.CD004435.pub3.
- Results publication: PubMed 11463584Svanborg E. Upper airway nerve lesions in obstructive sleep apnea. Am J Respir Crit Care Med. 2001 Jul 15;164(2):187-9. doi: 10.1164/ajrccm.164.2.2105010c. No abstract available.
- Results publication: PubMed 21271605Sunnergren O, Brostrom A, Svanborg E. Soft palate sensory neuropathy in the pathogenesis of obstructive sleep apnea. Laryngoscope. 2011 Feb;121(2):451-6. doi: 10.1002/lary.21371.
- Results publication: PubMed 10894423Jaghagen EL, Berggren D, Isberg A. Swallowing dysfunction related to snoring: a videoradiographic study. Acta Otolaryngol. 2000 Mar;120(3):438-43. doi: 10.1080/000164800750000702.
- Results publication: PubMed 14709606Levring Jaghagen E, Franklin KA, Isberg A. Snoring, sleep apnoea and swallowing dysfunction: a videoradiographic study. Dentomaxillofac Radiol. 2003 Sep;32(5):311-6. doi: 10.1259/dmfr/29209140.
- Results publication: PubMed 15768818Jaghagen EL, Berggren D, Dahlqvist A, Isberg A. Prediction and risk of dysphagia after uvulopalatopharyngoplasty and uvulopalatoplasty. Acta Otolaryngol. 2004 Dec;124(10):1197-203. doi: 10.1080/00016480410017954.
- Results publication: PubMed 18720519Jaghagen EL, Bodin I, Isberg A. Pharyngeal swallowing dysfunction following treatment for oral and pharyngeal cancer--association with diminished intraoral sensation and discrimination ability. Head Neck. 2008 Oct;30(10):1344-51. doi: 10.1002/hed.20881.
- Results publication: PubMed 25348130Camacho M, Certal V, Abdullatif J, Zaghi S, Ruoff CM, Capasso R, Kushida CA. Myofunctional Therapy to Treat Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Sleep. 2015 May 1;38(5):669-75. doi: 10.5665/sleep.4652.
- Results publication: PubMed 26924256Hagg M, Tibbling L. Effect of IQoro(R) training on impaired postural control and oropharyngeal motor function in patients with dysphagia after stroke. Acta Otolaryngol. 2016 Jul;136(7):742-8. doi: 10.3109/00016489.2016.1145797. Epub 2016 Feb 29.
- Individual participant dataSharing planned: No. Data will be shared with other researchers upon request. The data will be anonymized before sharing to avoid being traced back to a single study participant.
Related trials for Sleep Apnea, Obstructive
Enrolling by invitation
Myofunctional Therapy for Obstructive Sleep Apnea
Obstructive Sleep Apnea
Recruiting
A Study of the Sleepnet Elara APAP Device
Sleep Apnea - Obstructive
Not yet recruiting
Testing Settings of NovaResp's cMAP® Software During Home PAP Therapy
Obstructive Sleep Apnea
Not yet recruiting
Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea With Complete Concentric Collapse
Obstructive Sleep Apnea
Active, not recruiting
The Impact of Technology in Obstructive Sleep Apnea Myofunctional Therapy
Obstructive Sleep Apnea (OSA), Snoring
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thorbjörn Holmlund, PhD principal investigator
Region Västerbotten
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing IQoro, eXciteosa and Grouptraining in people with Sleep Apnea, Obstructive and Snoring, run by Region Västerbotten at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 29 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Sweden, Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Apnea-hypopnea index (AHI) (time frame: 90 days. Between first measurement (inclusion in study at baseline) and second measurement (at follow-up after 90 days of intervention or serving as control)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06330116, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2025.